AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, and listings, of claims in the Application:

Listing of Claims

1. (Currently amended) A compound of the Formula (I-1):



I-1

wherein:

X is alkylene ~~optionally interrupted by one or more -O- groups~~;

Z is -C(O)-;

R_{1-1} is selected from the group consisting of:

hydrogen,

alkyl,

phenyl,

$-N(CH_3)(OCH_3)$, and

alkyl or phenyl, substituted by one or more substituents selected from the group consisting of:

halogen,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy, and

alkyl; and

R_2 is selected from the group consisting of:

hydrogen,

alkyl,

hydroxyalkyl, and

alkyloxyalkyl;

R_A and R_B are taken together to form either a fused aryl ring that is unsubstituted or substituted by one or more R groups, or a fused 5 to 7 membered saturated ring that is unsubstituted or substituted by one or more R_a groups;

R is selected from the group consisting of:

fluoro,

alkyl,

haloalkyl,

alkoxy, and

$-N(R_9)_2$; and

R_a is selected from the group consisting of:

halogen,

hydroxy,

alkyl,

alkenyl,

haloalkyl,

alkoxy,

alkylthio, and

$-N(R_9)_2$;

or a pharmaceutically acceptable salt thereof.

2. (Currently amended) A compound of the Formula (I-2):



I-2

wherein:

X is alkylene ~~optionally interrupted by one or more -O- groups~~;

n is an integer from 0 to 4;

Z is -C(O)-;

R_{1-1} is selected from the group consisting of:

hydrogen,

alkyl,

phenyl,

$-N(CH_3)(OCH_3)$, and

alkyl or phenyl, substituted by one or more substituents selected from the group consisting of:

halogen,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy, and

alkyl;

R is selected from the group consisting of:

fluoro,

alkyl,

haloalkyl,

alkoxy, and

$-N(R_9)_2$;

R_2 is selected from the group consisting of:

hydrogen,

alkyl,

hydroxyalkyl, and

alkyloxyalkyl; and

R_9 is selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

3.-4. (Canceled)

5. (Currently amended) A compound of the Formula (Ia):



Ia

wherein:

X is alkylene ~~optionally interrupted by one or more -O- groups~~;

n is an integer from 0 to 4;

R_{1-1} is selected from the group consisting of:

hydrogen,

alkyl,

phenyl,

$-N(CH_3)(OCH_3)$, and

alkyl or phenyl, substituted by one or more substituents selected from the group consisting of:

halogen,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy, and

alkyl;

R is selected from the group consisting of:

fluoro,

alkyl,

haloalkyl,

alkoxy, and

-N(R_9)$_2$;

R_2 is selected from the group consisting of:

hydrogen,

alkyl,

hydroxyalkyl, and

alkyloxyalkyl; and

R_9 is selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

6.-7. (Canceled)

8. (Currently amended) A compound of the Formula (Ie):



Ie

wherein:

X is alkylene ~~optionally interrupted by one or more -O- groups~~;

n is an integer from 0 to 4;

R is selected from the group consisting of:

fluoro,

alkyl,

alkoxy,

haloalkyl, and

$-N(R_9)_2$;

R_2 is selected from the group consisting of:

hydrogen,

alkyl,

hydroxyalkyl, and

alkyloxyalkyl; and

R_9 is selected from the group consisting of hydrogen and alkyl;

or a pharmaceutically acceptable salt thereof.

9.-10. (Canceled)

11. (Previously presented) The compound or salt of claim 2 wherein n is 0.

12.-17. (Canceled)

18. (Previously presented) The compound or salt of claim 1 wherein R_{1-1} is selected from the group consisting of phenyl, alkyl, and $-N(CH_3)OCH_3$.

19. (Canceled)

20. (Currently amended) The compound or salt of claim 1 wherein X is [[a]] C_{1-6} alkylene ~~or $(CH_2)_{2-4}O(CH_2)_{1-3}$~~.

21. (Currently amended) The compound or salt of claim 20 wherein X is selected from the group consisting of $-(CH_2)_{1-6}-$, $-CH_2-C(CH_3)_2-$, ~~$-(CH_2)_2-O-CH_2-$~~, ~~$-(CH_2)_3-O-CH_2-$~~, and $-CH_2-C(CH_3)_2-CH_2-$.

22. (Previously presented) The compound or salt of claim 1 wherein R_{1-1} is selected from the group consisting of alkyl and phenyl.

23. (Previously presented) The compound or salt of claim 1 wherein R_{1-1} is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, cyclopentyl, *n*-hexyl, cyclohexyl, phenyl, 4-chlorophenyl and 2,4-dichlorophenyl.

24.-25. (Canceled)

26. (Previously presented) The compound or salt of claim 1 wherein R_2 is selected from the group consisting of hydrogen, hydroxymethyl, methyl, ethyl, *n*-propyl, *n*-butyl, ethoxymethyl, and 2-methoxyethyl.

27.-28. (Canceled)

29. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 in combination with a pharmaceutically acceptable carrier.

30. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal.

31. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

32. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

33.-35. (Canceled)

36. (Currently amended) The compound or salt of claim 2 wherein X is [[a]] C_{1-6} alkylene ~~or $-(CH_2)_{2-4}-O-(CH_2)_{1-3}-$~~.

37. (Currently amended) The compound or salt of claim 36 wherein X is selected from the group consisting of $-(CH_2)_{1-6}-$, $-CH_2-C(CH_3)_2-$, ~~$-(CH_2)_2-O-CH_2-$, $-(CH_2)_3-O-CH_2-$,~~ and $-CH_2-C(CH_3)_2-CH_2-$.

38. (Previously presented) The compound or salt of claim 2 wherein R_{1-1} is selected from the group consisting of alkyl and phenyl.

39. (Previously presented) The compound or salt of claim 2 wherein R_{1-1} is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, cyclopentyl, *n*-hexyl, cyclohexyl, phenyl, 4-chlorophenyl and 2,4-dichlorophenyl.

40. (Canceled)

41. (Previously presented) The compound or salt of claim 2 wherein R_2 is selected from the group consisting of hydrogen, hydroxymethyl, methyl, ethyl, *n*-propyl, *n*-butyl, ethoxymethyl, and 2-methoxyethyl.

42. (Previously presented) A pharmaceutical composition comprising a therapeutically

effective amount of a compound or salt of claim 2 in combination with a pharmaceutically acceptable carrier.

43. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.

44.-53. (Canceled)

54. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 8 in combination with a pharmaceutically acceptable carrier.

55. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 8 to the animal.